GlassScriptPhysician profile
Nikhil S Parikh
NPI 1336254234
$7,655.69
in general payments reported to CMS, 2019-2025
32 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,403 · 2020: $678 · 2021: $1,492 · 2022: $1,502 · 2023: $1,483 · 2024: $978 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,049.93 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $943.19 | 2021-2024 | Farxiga, Breztri, Lokelma |
| Abbvie INC. | $749.53 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.86 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $493.00 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $396.22 | 2019-2023 | Eliquis |
| Amgen INC. | $308.67 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $300.65 | 2019-2020 | |
| Amarin Pharma, INC. | $282.24 | 2019-2021 | |
| Esperion Therapeutics, INC. | $243.18 | 2020-2021 | |
| Lilly USA, LLC | $238.48 | 2019-2023 | Mounjaro |
| Pfizer INC. | $195.97 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $177.35 | 2022-2024 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $171.71 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $137.00 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $136.68 | 2023-2024 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.56 | 2021-2022 | |
| Novo Nordisk INC | $124.88 | 2019 | |
| Ferring Pharmaceuticals INC. | $123.58 | 2023 | Rebyota |
| Sk Life Science, INC. | $123.01 | 2022 | |
| Glaxosmithkline, LLC. | $121.55 | 2024 | Arexvy |
| Gilead Sciences, INC. | $120.07 | 2025 | Epclusa |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $79.14 | 2023-2024 | Inpefa |
| Arbor Pharmaceuticals, INC. | $52.50 | 2021 | |
| Acadia Pharmaceuticals INC | $28.72 | 2022-2023 | Nuplazid |
| Evoke Pharma, INC. | $27.23 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.83 | 2020-2022 | |
| Ucb, INC. | $14.03 | 2023 | Briviact |
| Otsuka America Pharmaceutical, INC. | $13.98 | 2023 | Nuedexta |
| Merck Sharp & Dohme LLC | $13.85 | 2021 | |
| Sumitomo Pharma America, INC. | $13.10 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.